title: Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne.
abstract: Talarozole, being developed by Barrier Therapeutics Inc under license from Johnson & Johnson, is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne. Phase II clinical trials of an oral formulation of talarozole in patients with psoriasis and with acne, and a phase I clinical trial of a topical formulation have been completed. At the time of publication, Barrier Therapeutics had suspended the development of talarozole as part of a series of cost-cutting initiatives; the company had also been acquired by Stiefel Laboratories Inc. No formal announcement had been made regarding the further development of talarozole.
authors.affiliation: University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07101, USA. geriaan@umdnj.edu
authors.forename: Aanand N
authors.initials: AN
authors.lastname: Geria
authors.forename: Noah S
authors.initials: NS
authors.lastname: Scheinfeld
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000818:Animals; D052160:Benzothiazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D014212:Tretinoin / Q000378:metabolism*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D052160:Benzothiazoles; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D014230:Triazoles; D014212:Tretinoin; C406527:R 115866